New Thymoglobulin Data Expected to be Presented At the 2001 American Society of Hematology Meeting.Business Editors/Medical Writers FREMONT, Calif.--(BW HealthWire)--Nov. 28, 2001 SangStat Medical Corporation (Nasdaq:SANG) expects new data on Thymoglobulin(R) (Anti-thymocyte Globulin Anti-thymocyte globulin (ATG) is an infusion of rabbit-derived antibodies against human T cells which is used in the prevention and treatment of acute rejection in organ transplantation and therapy of aplastic anemia. , (Rabbit)) to be presented at the American Society of Hematology (ASH) meeting which is scheduled to convene from December 7-11, 2001 in Orlando, Florida The city of Orlando is a major city in central Florida and is the county seat of Orange County, Florida. According to the 2000 census, the city population was 185,951. A 2006 U.S. . The U.S. Food and Drug Administration approved Thymoglobulin, a pasteurized pas·teur·ize tr.v. pas·teur·ized, pas·teur·iz·ing, pas·teur·iz·es To subject (a beverage or other food) to pasteurization. pas anti-thymocyte rabbit immunoglobulin, for use in conjunction with immunosuppressive medications in the treatment of acute renal rejection episodes. SangStat believes that a total of 25 Thymoglobulin abstracts will be presented at ASH. Researchers are expected to report on the results of several clinical studies, including: -- Abstract 2773-Low Dose Antithymocyte Globulin Incorporated into graft-versus-host disease (GVHD) Prophylaxis for Matched Related Donor Stem Cell Transplantation Results in Low Morbidity and No Mortality from Acute GVHD. Lead Investigator, James A. Russell, M.D., Christopher Brown Alberta BMT Program, Alberta, Canada -- Abstract 5270-Safety and efficacy of Nonmyeloablative Allogeneic Stem Cell Transplantation in an Elderly Population Using Cladiribine, Melphalan, and Rabbit-Derived Antithymocyte Globulin. Lead Investigator, Jeffrey Andrey, Blood & Marrow Transplantation Program, Scripps Clinic, Honolulu, HI, USA Abstracts of these studies and others being presented at ASH 2001 can be found at www.abstracts-on-line.com/abstracts/HEM/aol.asp. Thymoglobulin Thymoglobulin, which was introduced to the US market in 1999, is a pasteurized anti-thymocyte rabbit immunoglobulin indicated for the treatment of renal transplant renal transplant Transplantation of a kidney from a living donor or cadaver to a recipient with ESRD Indications–children Congenital kidney/GU tract malformations–42%; focal segmental glomerulosclerosis-12% and others; 31% of children were ≤ age 5 acute rejection, in conjunction with concomitant immunosuppression immunosuppression Suppression of immunity with drugs, usually to prevent rejection of an organ transplant. Its aim is to allow the recipient to accept the organ permanently with no unpleasant side effects. . Thymoglobulin is made up of a variety of antibodies that recognize key receptors on T-cells, the cells of a transplant recipient's immune system immune system Cells, cell products, organs, and structures of the body involved in the detection and destruction of foreign invaders, such as bacteria, viruses, and cancer cells. Immunity is based on the system's ability to launch a defense against such invaders. that recognize and ultimately reject foreign objects such as a transplant. Common adverse reactions adverse reactions, n.pl unfavorable reactions resulting from administration of a local anesthetic; responsible factors include the drug used, concentration, and route of administration. , which are often transient, include fever, infections, and thrombocytopenia Thrombocytopenia Definition Thrombocytopenia is an abnormal drop in the number of blood cells involved in forming blood clots. These cells are called platelets. . Thymoglobulin is contraindicated in patients with known allergy to rabbit proteins, an acute viral illness, or a history of anaphylaxis anaphylaxis (ăn'əfəlăk`sĭs), hypersensitive state that may develop after introduction of a foreign protein or other antigen into the body tissues. during rabbit immunoglobulin administration. Thymoglobulin should only be used by physicians experienced in immunosuppressive therapy Immunosuppressive therapy Medical treatment in which the immune system is purposefully thwarted. Such treatment is necessary, for example, to prevent organ rejection in transplant cases. in the management of renal transplant patients. SangStat SangStat is a global biotechnology company building on its foundation in transplantation to discover, develop and market high value therapeutic products in the transplantation, immunology and hematology/oncology areas. Since 1988, SangStat has been dedicated to improving the outcome of organ and bone marrow transplantation Bone Marrow Transplantation Definition The bone marrow—the sponge-like tissue found in the center of certain bones—contains stem cells that are the precursors of white blood cells, red blood cells, and platelets. through the development and marketing of products to address all phases of transplantation in the worldwide market. SangStat's US headquarters are in Fremont, California. SangStat also maintains a strong European presence, including direct sales and marketing forces in France, Germany, Italy, Spain, and the U.K., and distributors throughout the rest of the world. SangStat was selected by Deloitte & Touche as a 2001 Technology Fast 50 Gold Circle firm. SangStat's stock is traded on the Nasdaq under the symbol "SANG." The company's web site is located at www.sangstat.com. The abstracts, papers and presentations noted above reflect the views of their authors. They should not be relied upon as sentiments by or endorsements from SangStat. This press release and the referenced abstracts, papers and presentations may contain forward-looking statements that involve risks and uncertainties, including statements regarding product development, clinical trials, timeline and the regulatory process. Forward-looking statements reflect the author's current views with respect to future events. Actual results may vary materially and adversely from those anticipated, believed, estimated, or otherwise indicated. SangStat disclaims any obligation to update these forward-looking statements for subsequent events. There can be no assurance that Thymoglobulin will be safe, effective or capable of being manufactured in commercial quantities at an economical cost, that it will not infringe the proprietary rights of others, that it will achieve market acceptance or that it will receive regulatory approvals for other indications. Thymoglobulin is not approved for the clinical uses described in the two abstracts and no commitment or prediction should be inferred regarding clinical trials or marketing applications or approvals for those uses or other indications. For a discussion of these and other factors that might result in different outcomes, see "Risk Factors" in SangStat's 2000 Annual Report on Form 10-K Form 10-K A report required by the SEC from exchange-listed companies that provides for annual disclosure of certain financial information. Form 10-K See 10-K. , its 2001 quarterly reports on Form 10-Q Form 10-Q See 10-Q. and other documents (including registration statements on Form S-3) filed with the Securities and Exchange Commission. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion